Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
05/2007
05/31/2007US20070122484 Parenterally administrable microparticles
05/31/2007US20070122483 Fluocinolone acetonide drug substance polymorphic interconversion
05/31/2007US20070122482 Method for preparing modified release pharmaceutical compositions
05/31/2007US20070122481 Rapid dissolving tablets containing capecitabine and releasing the drug in pulses about six to about twelve hours after administration
05/31/2007US20070122480 Sustained release formulations
05/31/2007US20070122479 Threo-DOPS controlled release formulation
05/31/2007US20070122478 Extended release composition containing tramadol
05/31/2007US20070122477 Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency
05/31/2007US20070122476 Storage stable thyroxine active drug formulations and methods for their production
05/31/2007US20070122475 Taste masking composition
05/31/2007US20070122474 Pharmaceutical preparation comprising an active dispersed on a matrix
05/31/2007US20070122473 Aminosugar and/or glycosaminoglycan composition having therapeutic use
05/31/2007US20070122472 Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability
05/31/2007US20070122471 Method of improving suitability for granulation
05/31/2007US20070122470 New Combination Dosage Form
05/31/2007US20070122469 Method for producing a vesicle dispersion
05/31/2007US20070122468 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
05/31/2007US20070122467 Anaesthetic formulations
05/31/2007US20070122466 Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
05/31/2007US20070122465 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
05/31/2007US20070122464 Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis
05/31/2007US20070122460 Hot-flash wipes and clothing
05/31/2007US20070122458 Nicotine and Chocolate Compositions
05/31/2007US20070122457 Nicotine and Chocolate Compositions
05/31/2007US20070122450 Treatment of ophthalmic conditions
05/31/2007US20070122447 Shaped bodies and methods for their production and use
05/31/2007US20070122446 Implants for treatment of symptomatic or degenerated intervertebral discs
05/31/2007US20070122440 Methods for producing nanoparticles
05/31/2007US20070122435 Topical dapsone for the treatment of acne
05/31/2007US20070122433 Less painful immunogenic composition of a hydrophobic protein; solubilizing hydrophobic protein with a zwitterionic detergent to make a composition that is then altered; meningitis or gonorrhea
05/31/2007US20070122425 fusion protein comprising a periplasmic targeting signal and at least one antimicrobial peptide; use as microbiocides; from Gram negative bacteria transformed host cell; nontoxic and proteolytic non-degradation, simple, inexpensive recovery of the peptide; industrial scale production; on medical devices
05/31/2007US20070122423 Derp1 and proderp1 allergen derivatives
05/31/2007US20070122418 Compositions and methods for the pulmonary delivery of aerosolized medicaments
05/31/2007US20070122411 Solid forms of anti-egfr antibodies
05/31/2007US20070122400 Composition having liver function protecting effect
05/31/2007US20070122398 Encapsulated hydrophilic compounds
05/31/2007US20070122397 Probiotic storage and delivery
05/31/2007US20070122394 administering a VEGFR modulating agent that comprises placental growth factor; a growth factor that binds and activates Flt-1 such as PIGF or VEGF-B, an anti-Flt-1 agonistic antibody or a small molecule agonist
05/31/2007US20070122388 Tissue graft compositions and methods for producing same
05/31/2007US20070122362 Hydrogel sheets and shapes for oral care
05/31/2007US20070122355 Rapidly absorbing oral formulations of pde 5 inhibitors
05/31/2007US20070122354 possess superior aerosol properties, even in the absence of stabilizing carriers or excipients; inhalants; when administered to the deep lung, are useful for treating allergic diseases, such as asthma, atopy, and atopic dermatitis
05/31/2007US20070122353 Drug condensation aerosols and kits
05/31/2007US20070122352 Inhalation Drug Combinations
05/31/2007US20070122351 Inhalation Drug Combinations
05/31/2007US20070122350 Safe and effective methods of administering therapeutic agents
05/31/2007US20070122349 Measuring Particle Size Distribution in Pharmaceutical Aerosols
05/31/2007US20070122348 For preventing oral abuse of an oral opioid formulation; provides a negative, "aversive" experience when a large amount of the opioid, e.g., about 2-3 times the usually prescribed dose, is taken by or administered to a physically dependent subject
05/31/2007DE102005056530A1 New amphiphilic block copolymer containing polypentadecalactone as hydrophobic component, useful e.g. as solubilizer or dispersant for pesticides and pharmaceuticals
05/31/2007DE10084749T5 Zugabe eines botanischen Extrakts zu einem behandelten Substrat für die Übertragung auf Haut Addition of a botanical extract to a treated substrate for transfer to skin
05/31/2007CA2652597A1 Nanoporous membrane and method of preparation thereof
05/31/2007CA2630772A1 Respirable powders
05/31/2007CA2630738A1 Immunostimulatory oligoribonucleotides
05/31/2007CA2630248A1 Machine and method for pharmaceutical and pharmaceutical-like product assembly
05/31/2007CA2630072A1 Pharmaceutical compositions comprising buprenorphine
05/31/2007CA2629560A1 Pharmaceutical compositions comprising buprenorphine
05/31/2007CA2629193A1 Coatable compositions, coatings derived therefrom and microarrays having such coatings
05/31/2007CA2629091A1 Oil-in-water emulsion and its use for the delivery of functionality
05/31/2007CA2629082A1 Aerosol formulation for inhalation containing an anticholinergic agent
05/31/2007CA2629074A1 Aerosol formulation for inhalation containing an anticholinergic agent
05/31/2007CA2629073A1 Aerosol formulation for inhalation containing an anticholinergic agent
05/31/2007CA2629070A1 Aerosol formulation for inhalation containing an anticholinergic agent
05/31/2007CA2628947A1 Aerosol formulation for inhalation containing an anticholinergic agent
05/31/2007CA2628917A1 Pharmaceutical compositions
05/31/2007CA2626933A1 Pharmaceutical composition
05/31/2007CA2625404A1 Bilayer tablet comprising telmisartan and diuretic
05/31/2007CA2623018A1 Pharmaceutical compositions of telmisartan
05/30/2007EP1790687A2 Cereal beta glucan compositions, methods of preparation and uses thereof
05/30/2007EP1790659A2 Polypeptides of pseudomonas aeruginosa
05/30/2007EP1790657A1 pH-switchable transmembrane peptides as stimulators of membrane fusion
05/30/2007EP1790347A1 High dose ibandronate formulation
05/30/2007EP1790338A1 Therapeutic agent for keratoconjunctiva disorder
05/30/2007EP1790336A1 Composition for capsule film, capsule film, and capsule made with the same
05/30/2007EP1790335A1 Composition and its use for the manufacture of a medicament for treating, prophylactically treating, preventing cancer and/or infections in the urinary tract
05/30/2007EP1790334A2 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
05/30/2007EP1790333A1 Gastroresistant tablet comprising a butyric acid compound
05/30/2007EP1790332A1 Vaccine for oral administration
05/30/2007EP1790331A1 Use of pyridoxal-5-phosphate for the treatment of cardiovascular and related pathologies
05/30/2007EP1790235A1 Method for producing capsinoid-containing microcapsule
05/30/2007EP1789689A2 Carbon and metal nanomaterial composition and synthesis
05/30/2007EP1789366A1 Mesoporous nanoparticles
05/30/2007EP1789139A1 Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl|amino|-2-pyrimidinyl|amino|benzonitrile
05/30/2007EP1789107A2 Medical stent provided with inhibitors of atp synthesis
05/30/2007EP1789078A1 Pulmonary delivery of a nerve agent neutralizing enzyme
05/30/2007EP1789077A2 Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning
05/30/2007EP1789075A2 Absorption enhancers for drug administration
05/30/2007EP1789060A1 Compositions comprising compounds capable of forming a reversible bond or association with gaseous nitric oxide
05/30/2007EP1789057A2 Neuroprotective effect of solubilized udca in focal ischemic model
05/30/2007EP1789030A2 Medical implant provided with inhibitors of atp synthesis
05/30/2007EP1789029A2 Methods and compositions for the treatment of cell proliferation
05/30/2007EP1789026A2 Method for systemic bio-correction of an organism
05/30/2007EP1789025A2 Device for transdermal delivery of active principles
05/30/2007EP1789024A2 Controlled regional oral delivery
05/30/2007EP1789023A2 Marking articles
05/30/2007EP1789022A2 Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
05/30/2007EP1789021A2 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
05/30/2007EP1789020A2 Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
05/30/2007EP1789019A2 Powders containing novel oligosaccharide mixtures and methods for producing the same
05/30/2007EP1789018A1 Enhanced delivery of drug compositions to treat life threatening infections
05/30/2007EP1789017A2 Phenolic antiseptic compositions and methods of use
1 ... 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 ... 2991